CG Oncology (CGON) Stock Price, News & Analysis

Company Overview

CG Oncology, Inc. (NASDAQ: CGON) is a clinical-stage biotechnology company dedicated to the development of next-generation immuno-oncology therapies. The company’s core focus lies in leveraging novel oncolytic viral platforms and targeted immunomodulatory agents to activate the body’s immune system against solid tumors. Its lead candidate, CG0070, is an oncolytic adenovirus engineered to selectively replicate within and destroy bladder cancer cells while stimulating a localized immune response via granulocyte-macrophage colony-stimulating factor (GM‐CSF).

In addition to its oncolytic virus pipeline, CG Oncology is advancing a proprietary immunomodulator licensed from European collaborators. This fusion protein is designed to bind tumor-associated superantigens and activate tumor-infiltrating T cells, broadening the company’s reach into multiple oncology indications. Together, these assets reflect a diversified strategy aimed at both direct tumor eradication and systemic immune activation.

The company conducts multi-center clinical trials across North America and Europe, collaborating with leading academic institutions and contract research organizations to evaluate safety and efficacy in patients with advanced cancers. CG Oncology’s global approach enables rapid patient enrollment and regulatory engagement, positioning its candidates for potential registration in key markets.

Founded in the early 2010s as a spinout focusing on oncolytic viral research, CG Oncology has grown under the leadership of an experienced management team with deep roots in biotechnology and pharmaceutical development. Supported by a board of directors with expertise spanning immunology, virology and oncology drug commercialization, the company continues to pursue strategic partnerships and funding opportunities to advance its pipeline toward commercialization.

Key Stats

• Today's Range: $24.50 to $26.78
• 50-Day Range: $24.17 to $28.46
• 52-Week Range: $14.80 to $40.47
• Volume: 1.95 million shs
• Average Volume: 874,441 shs
• Market Capitalization: $1.98 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.30
• Consensus Rating: Buy

CG Oncology Stock Analysis - MarketRank™

CG Oncology scored higher than 50% of companies evaluated by MarketBeat, and ranked 516th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

CG Oncology has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

CG Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CG Oncology is -17.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CG Oncology is -17.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CG Oncology has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.16% of the float of CG Oncology has been sold short.

Short Interest Ratio / Days to Cover

CG Oncology has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in CG Oncology has recently increased by 1.90%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CG Oncology does not currently pay a dividend.

Dividend Growth

CG Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

25.16% of the float of CG Oncology has been sold short.

Short Interest Ratio / Days to Cover

CG Oncology has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in CG Oncology has recently increased by 1.90%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.40

News Sentiment

CG Oncology has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for CG Oncology this week, compared to 5 articles on an average week.

MarketBeat Follows

4 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $86,760.00 in company stock.

Percentage Held by Institutions

Only 26.56% of the stock of CG Oncology is held by institutions.

CGON Stock Analysis - Frequently Asked Questions

How have CGON shares performed this year?

CG Oncology's stock was trading at $28.68 at the beginning of 2025. Since then, CGON shares have decreased by 9.3% and is now trading at $26.01.

How were CG Oncology's earnings last quarter?

CG Oncology, Inc. (NASDAQ:CGON) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.53 million. CG Oncology had a negative net margin of 15,945.17% and a negative trailing twelve-month return on equity of 16.71%.

When did CG Oncology IPO?

CG Oncology (CGON) raised $380 million in an IPO on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share.

Who are CG Oncology's major shareholders?

Top institutional shareholders of CG Oncology include AMI Asset Management Corp (0.05%), Wesbanco Bank Inc. (0.04%) and Mirae Asset Global Investments Co. Ltd.. Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche, Vijay Kasturi and Leonard E Post.
View institutional ownership trends.

How do I buy shares of CG Oncology?

Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CG Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/22/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CGON
• Previous Symbol: NASDAQ:CGON
• CIK: 1991792
• Web: cgoncology.com
• Phone: 949-419-6203
• Fax: N/A
• Employees: 61
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CG Oncology: $55.30
• High Price Target: $75.00
• Low Price Target: $23.00
• Potential Upside/Downside: +112.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.08
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$88.04 million
• Net Margins: -15,945.17%
• Pretax Margin: -15,945.17%
• Return on Equity: -16.71%
• Return on Assets: -16.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 30.97
• Quick Ratio: 30.97

Sales & Book Value

• Annual Sales: $1.14 million
• Price / Sales: 1,739.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.63 per share
• Price / Book: 2.70

Miscellaneous

• Outstanding Shares: 76,220,000
• Free Float: N/A
• Market Cap: $1.98 billion
• Optionable: Optionable
• Beta: 0.86